| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | 86.5 | 93.9 |
| Gross profit | 26.1 | 27.0 |
| Profit before tax | 10.7 | -21.2 |
| Net income | 10.1 | -21.7 |
| EPS (diluted, $ a share) | $0.07 | $-0.18 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -7.9% |
|---|---|
| Gross margin | 30.1% |
| Operating margin | -42.2% |
10-Q filed with the SEC, NASDAQ: ARAY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Accuray Inc: key numbers
- Share price
- $2.55Close, Nov 16
- Market cap
- $306M
- Shares outstanding
- 120.16MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Accuray Inc
All →Accuray Capital Raise of $15M
Accuray completed a $55 million financing transaction with its primary lender TCW, involving the issuance of 55,000 shares of Series A Convertible Preferred Stock. The deal includes $15 million in new cash capital and the conversion of $40 million of existing debt into equity, significantly deleveraging the balance sheet.
- Value
- $15M
- Counterparty
- TCW Asset Management Company LLC
Accuray Reverse Stock Split
Accuray Incorporated announced a 1-for-40 reverse stock split of its common stock, effective November 9, 2026. The split will reduce outstanding shares from approximately 120.2 million to 3.0 million and is intended to increase the per-share trading price to regain compliance with Nasdaq's minimum bid price requirement.
Accuray Financial Results
Accuray reported fiscal 2027 first quarter results with total net revenue of $86.5 million, an 8% decrease year-over-year, primarily due to lower product revenue. The company recorded a $35.4 million non-cash goodwill impairment charge but noted that transformation initiatives generated $13 million in cost and margin improvements.
“As I said on our last call, fiscal 2026 was a year of transformation, and fiscal 2027 is about execution. During the first quarter, we made progress across several areas. Service margins improved, operating expenses remained well controlled, we strengthened our financial position, and we advanced our innovation roadmap through strategic partnerships with RaySearch and Samsung NeuroLogica.”
Steve La Neve, President and Chief Executive Officer
“At the same time, we see a clear opportunity to improve product and order performance. The customer engagement we saw at ASTRO, the growing clinical evidence supporting precision radiation therapy, and the opportunities created by our innovation strategy reinforce our confidence in the direction we are taking.”
Steve La Neve, President and Chief Executive Officer
Accuray Leadership Change
Mika Nishimura, a Class II director and Chairperson of the Compensation Committee, has informed the Board of her intention not to stand for re-election at the upcoming 2026 annual meeting of stockholders. Her departure is not due to any disagreement with the company and she will continue to serve until the conclusion of the November 2026 meeting.
Accuray Reverse Stock Split
Accuray stockholders approved a reverse stock split at a ratio between 1-for-15 and 1-for-40 at a special meeting, alongside an increase in authorized shares and a financing-related stock issuance. The company also appointed Richard A. Meier to its Board of Directors and Compensation Committee. These actions are part of a comprehensive financial restructuring plan with TCW Asset Management Company LLC to improve the balance sheet and provide liquidity.